Ceritinib is a novel triple negative breast cancer therapeutic agent

BACKGROUND: Triple-negative breast cancers (TNBCs) are clinically aggressive subtypes of breast cancer. TNBC is difficult to treat with targeted agents due to the lack of commonly targeted therapies within this subtype. Androgen receptor (AR) has been detected in 12–55% of TNBCs. AR stimulates breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Shengli, Yousefi, Hassan, Savage, Isabella Van, Okpechi, Samuel C., Wright, Maryl K., Matossian, Margarite D., Collins-Burow, Bridgette M., Burow, Matthew E., Alahari, Suresh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241294/
https://www.ncbi.nlm.nih.gov/pubmed/35768871
http://dx.doi.org/10.1186/s12943-022-01601-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241294/
https://www.ncbi.nlm.nih.gov/pubmed/35768871
http://dx.doi.org/10.1186/s12943-022-01601-0

Ejemplares similares